Cefmenoxime is a semisynthetic cephalosporin that displays a broad spectrum of activity against many grampositive and gram-negative bacteria (1, 6). Recent studies in adults have demonstrated the clinical efficacy of cefmenoxime in a wide variety of infections, including urinary tract infections, pneumonia, and septicemia (3, 5). The current study was initiated to determine the clinical pharmocokinetics of cefmenoxime and to evaluate its clinical efficacy and safety in the treatment of bacterial infections in children.
Cefmenoxime is a semisynthetic cephalosporin that displays a broad spectrum of activity against many grampositive and gram-negative bacteria (1, 6) . Recent studies in adults have demonstrated the clinical efficacy of cefmenoxime in a wide variety of infections, including urinary tract infections, pneumonia, and septicemia (3, 5) . The current study was initiated to determine the clinical pharmocokinetics of cefmenoxime and to evaluate its clinical efficacy and safety in the treatment of bacterial infections in children. Cefmenoxime levels. Patients receiving 30-min infusions had blood drawn for determination of trough and peak cefmenoxime levels in serum 30 min before and immediately after the infusion, respectively. Blood samples were obtained by venipuncture through a heparin lock. Samples were collected in tubes without anticoagulant. Serum was separated after centrifugation at 500 x g for 5 min and was kept frozen at -70°C until assayed. Drug levels were determined by the agar well diffusion technique (2) in Trypticase soy agar (BBL Microbiology Systems, Cockeysville, Md.) with Escherichia coli ATCC 25922. Cefmenoxime standards were prepared in normal human serum and ranged from 1 to 64 ,ug of cefmenoxime per ml.
MATERIALS AND METHODS
Susceptibility studies. Kirby-Bauer disk diffusion tests with a 30-,ug disk were performed for all bacterial isolates. MICs by tube dilution (7) one Streptococcus pyogenes (cervical adenitis), and one Haemophilus influenzae type b (periorbital cellulitis). Eradication was confirmed in 10 of these patients. The two children with wound infections involving E. coli showed clinical resolution of inflammation and purulent discharge, but at the completion of therapy a culture from the incision continued to grow E. coli. The youngster with a urinary tract infection secondary to Proteus mirabilis showed eradication of the organism, but the emergence of P. aeruginosa was seen in the follow-up urine cultures. All of the initial isolates were susceptible to cefmenoxime.
The remaining 10 patients, from whom we did not isolate any organisms, all appeared to respond satisfactorily with cefmenoxime. These patients included two children with cervical adenitis (who had surgical drainage), two children with pneumonia, one child with periorbital cellulitis, three children with urinary tract infection, two children with soft-tissue infection, and one child with superinfected intralobar pulmonary sequestration.
Cefmenoxime was administered without any significant toxicity. One child developed a generalized urticarial rash after 18 days of treatment, which resolved within 24 h of cessation of therapy. No side effects or laboratory abnormalities occurred in any patient. The mean peak and trough cefmenoxime concentrations were 55.0 ± 33.6 jig/ml (range, 15 to 130 gig/fnl; n = 12 and 1.1 ± 2.1 jig/ml (range, 0 to 6.2 gig/ml; n = 13), respectively, after the 30-min i.v. infusion.
DISCUSSION
Cefmenoxime compares favorably in vitro with the recently released broad-spectrum cephalosporins cefotaxime, moxalactam, and cefoperazone for gram-negative bacteria (6) . Cefmenoxime has greater in vitro activity against grampositive bacteria than does moxalactam, especially against S. pneumoniae, S. pyogenes, and S. aureus (1) .
In two recent clinical studies of cefmenoxime for the The mean peak concentration of cefmenoxime in serum in our patients after one 75-to 150-mg/kg dose was 55 p.g/ml after the 30-min i.v. infusion. In a study of single-dose pharmacokinetics of cefmenoxime in adults (4), the mean calculated peak levels after 60-min i.v. infusions of 500, 1,000, and 200 mg were 22.8, 41.6, and 94.5 ,ug/ml, respectively. Gombert et al. (3) found peak concentrations of 47 ig/ml after a 1-g dose and 95 ,ug/ml after a 2-g dose. The trough levels were 9 ,ug/ml. The pharmacokinetics were best described by a two-.compartment open model with a betaphase half-life of 55 min.
The results of this preliminary study demonstrated that cefmenoxime is a safe and efficacious antibiotic in the treatment of urinary tract infections, soft-tissue infections, and osteomyelitis in children.
